Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927883 | 0.89 | MCHR1 (0.69) | MCHR1HTR2C | |
| SCHEMBL929243 | 0.86 | MCHR1 (0.62) | MCHR1HTR2CNR1H4 | |
| SCHEMBL929262 | 0.86 | MCHR1 (0.62) | MCHR1HTR2CNR1H4 | |
| SCHEMBL13673962 | 0.82 | MCHR1 (0.61) | MCHR1HTR2C | |
| SCHEMBL928427 | 0.81 | MCHR1 (0.55) | MCHR1HTR2CGPR35 | |
| SCHEMBL567061 | 0.80 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL928389 | 0.80 | MCHR1 (0.61) | MCHR1HTR2C | |
| SCHEMBL926849 | 0.79 | MCHR1 (0.70) | MCHR1HTR2C | |
| SCHEMBL928429 | 0.79 | MCHR1 (0.53) | MCHR1 | |
| SCHEMBL926995 | 0.79 | MCHR1 (0.53) | MCHR1HTR2CGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009123194-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 81/4885NR1H4 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.